| ASSET | MONTH | % RETURN |
|---|---|---|
Xenetic Biosciences (XBIO) | January 2014 | 650% |
Empire Petroleum (EP) | January 2014 | 524.69% |
Live Ventures (LIVE) | January 2014 | 369.21% |
Capricor Therapeutics (CAPR) | January 2014 | 319.25% |
Ainos (AIMD) | January 2014 | 299.53% |
Scienture (SCNX) | January 2014 | 263.64% |
GT Biopharma (GTBP) | January 2014 | 177.78% |
Enveric Biosciences (ENVB) | January 2014 | 162% |
Ryvyl (RVYL) | January 2014 | 153.52% |
Harrow Health (HROW) | January 2014 | 151.82% |
Opus Genetics (IRD) | January 2014 | 125.49% |
Cytosorbents Crp (CTSO) | January 2014 | 118.75% |
Anixa Biosciences (ANIX) | January 2014 | 103.54% |
Intracellular Th (ITCI) | January 2014 | 94% |
Heritage Global (HGBL) | January 2014 | 93.55% |
Digimarc (DMRC) | January 2014 | 91.12% |
Savara (SVRA) | January 2014 | 86.91% |
Neurocrine Biosciences (NBIX) | January 2014 | 84.36% |
CorMedix (CRMD) | January 2014 | 83.06% |
Lightbridge (LTBR) | January 2014 | 81.63% |
CEL-SCI (CVM) | January 2014 | 79.66% |
PharmaCyte Biotech (PMCB) | January 2014 | 76.12% |
Siebert Financial (SIEB) | January 2014 | 76.05% |
Arbutus Biopharma (ABUS) | January 2014 | 75.6% |
Galectin Therapeutics (GALT) | January 2014 | 71.16% |
